Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 3.33B |
| Revenue (ttm) | 8.46M |
| Net Income (ttm) | n/a |
| Shares Out | 42.71M |
| EPS (ttm) | -8.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 112,801 |
| Open | 13.83 |
| Previous Close | 13.89 |
| Day's Range | 13.46 - 13.83 |
| 52-Week Range | 10.62 - 19.84 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Oct 28, 2021 |
About LYEL
Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines. We take a systematic, interrogative, cell biology-driven approach to overcome what we view as the two major barriers to successful ACT – (1) T cell exhaustion and (2) lack of durable stemness – through the application of our proprietary genetic and epigenetic reprogramming technologies, G...
Financial Performance
In 2020, LYEL's revenue was $7.76 million, an increase of 1,080.52% compared to the previous year's $657,000. Losses were -$204.47 million, 58.0% more than in 2019.
Financial StatementsNews
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...
Lyell Immunopharma Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...
Lyell Immunopharma IPO Registration Document (S-1)
Lyell Immunopharma, Inc. has filed to go public with an IPO on the NASDAQ.